Showing results (61-70 of 77) with videos related to
Sort By:
Pageof 8
The Lancet. Oncology|February 25, 2011
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation studyIrene M Ghobrial, Edie Weller, Ravi Vij, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myelomaPaul G Richardson, Edie Weller, Sundar Jagannath, et al.Blood|October 2, 2007
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieuYu-Tzu Tai, Myles Dillon, Weihua Song, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2013
Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patientsJacalyn Rosenblatt, Irit Avivi, Baldev Vasir, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2009
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathyPaul G Richardson, Wanling Xie, Constantine Mitsiades, et al.The Journal of Allergy and Clinical Immunology|January 23, 2023
The IL-4Rα Q576R polymorphism is associated with increased severity of atopic dermatitis and exaggerates allergic skin inflammation in miceBarbara Yang, Hazel Wilkie, Mrinmoy Das, et al.Haematologica|April 16, 2017
Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker ConsortiumWendy B C Stevens, Matias Mendeville, Robert Redd, et al.Blood|July 15, 2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myelomaPaul G Richardson, Emily Blood, Constantine S Mitsiades, et al.Blood|April 14, 2010
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myelomaPaul G Richardson, Edie Weller, Sagar Lonial, et al.Science Advances|December 20, 2023
NET formation is a default epigenetic program controlled by PAD4 in apoptotic neutrophilsYanfang Peipei Zhu, Mary Speir, ZheHao Tan, et al.Pageof 8